PREVALENCE OF BRCA1 AND BRCA2 MUTATIONS IN WOMEN WITH EARLY-ONSET BREAST CANCER

2025

Полный текст Открытый доступ: Hybrid Метаданные (CSL-JSON)
DOI 10.71000/d1xdm317
Достоверность данных 70 средняя
Как считается эта оценка

Складывается из проверяемых признаков самой записи: есть ли у статьи DOI, сколько независимых источников подтвердили её данные, заполнены ли обязательные поля и насколько свежо последнее подтверждение. Снижают оценку расхождения между источниками и отсутствие идентификатора. Значение от 80 означает, что запись опубликована без дополнительной проверки; от 60 до 79 — что она опубликована с пониженной достоверностью и ручная проверка желательна. Запись, выверенную редактором вручную, пересчёт не опускает ниже 90. Это оценка наших данных о статье, а не оценка самой статьи.

Аннотация

Background: Early-onset breast cancer poses significant clinical challenges due to its aggressive behavior and genetic predisposition. Mutations in the BRCA1 and BRCA2 genes are strongly linked to hereditary breast cancer, especially in younger patients. However, regional data on their prevalence remains limited in South Asian populations, particularly in Pakistan. Objective: To determine the prevalence of BRCA1 and BRCA2 gene mutations among women diagnosed with early-onset breast cancer in the Lahore region of Pakistan. Methods: A cross-sectional study was conducted over eight months involving 200 women aged ≤39 years with histologically confirmed breast cancer. Participants were recruited from three major oncology centers in Lahore. Clinical and demographic data were collected through structured interviews. Peripheral blood samples were analyzed using next-generation sequencing (NGS) for BRCA1/2 mutations. Statistical analysis was performed using SPSS v26, with significance set at p<0.05. Results: BRCA1 mutations were identified in 24 patients (12%) and BRCA2 mutations in 18 (9%). Variants of uncertain significance were found in 6 patients (3%), while 152 (76%) tested negative for both mutations. Mutation prevalence was significantly higher in patients with a family history of breast or ovarian cancer and among those with triple-negative breast cancer. BRCA1 mutations were most common in triple-negative cases (25%), while BRCA2 mutations showed a slightly more even distribution across subtypes. Conclusion: A considerable proportion of early-onset breast cancer patients in Pakistan carry BRCA mutations. These findings underscore the importance of routine genetic screening and tailored risk management strategies in young breast cancer patients, irrespective of family history.